Glen Harbor Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Glen Harbor Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$33K	Hold	408	–	–	﹤0.01%	1265
2019 Q2	$39K	Buy	408 +170	+71%	+$14.7K	﹤0.01%	1267
2019 Q1	$20K	Sell	238 -68	-22%	-$5.64K	﹤0.01%	1276
2018 Q4	$17K	Buy	+306	New	+$18.7K	﹤0.01%	1248

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Harbor Capital Management's RETA Position: Q3 2019 in Review

Glen Harbor Capital Management held its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) position steady in Q3 2019 at 408 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

Glen Harbor Capital Management first reported a position in RETA in Q4 2018 and has held it in 4 quarters since. The position peaked at $39K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

Glen Harbor Capital Management held 408 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $33K as of Q3 2019.
Glen Harbor Capital Management left its Reata Pharmaceuticals, Inc. Class A Common Stock share count unchanged in Q3 2019.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1265 holding.
Glen Harbor Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and has held it in 4 quarters since.
Glen Harbor Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $39K in Q2 2019.
164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.